AZ’s Dr Yunxia Bi joins ISP
pharmafile | March 30, 2011 | Appointment | Manufacturing and Production | appointment, manufacturing and production
ISP Pharmaceuticals has appointed Dr Yunxia (Vivian) Bi as technical director of its solubility initiative.
It is a newly-created position in which Dr Bi will oversee the development of technical data and information to support the use of ISP’s solubility-enhancing ingredient portfolio and solid dispersion development services by pharmaceutical formulators.
She previously served at AstraZeneca Pharmaceuticals in a research role as associate principal scientist.
Philip Strenger, senior VP of global pharmaceuticals, said: “ISP is pleased to appoint a scientist with experience in confronting the challenges in developing poorly soluble drugs to lead this important R&D initiative.
“Dr Bi knows the processes pharmaceutical makers follow when formulating poorly soluble entities and the general pathways pharmaceutical makers follow when commercialising such entities. We are confident Dr Bi will be an asset to companies that want to reduce the development timeline and costs associated with the development of poorly soluble drugs.”
Based in New Jersey, USA, International Specialty Products (ISP) is a leading global supplier of specialty chemicals and performance enhancing products.
Related Content

Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …






